Skip to content

What is PIMT (persistent isolated mild thrombocytopenia), and is it clinically significant?

Current as of 23 July 2026 · added 23 July 2026

Answer: Persistent isolated mild thrombocytopenia (PIMT) is a common reason for referral, and data to guide management are scant.

  • In one long-term report, the risk of developing a hematological disease was 26.4%, compared with 1.7% in matched healthy subjects.
  • There may be value in yearly or interval CBC follow-up, but the management remains unclear.
  • Patients with PIMT also have higher circulating levels of glycoprotein (GP)-specific antibodies; those with such antibodies have a 7-fold greater odds of developing ITP than those without (ASH abstract).

Source: Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia